Autologous Hematopoietic Stem Cell Transplantation for Adults With Acute Myeloid Leukemia

Cioch, Maria; Jawniak, Dariusz; Wach, Małgorzata; Mańko, Joanna; Radomska, Karolina; Borowska, H.; Szczepanek, Aleksandra; Hus, Marek

doi:10.1016/j.transproceed.2016.03.014

Cited by 8 publications

(6 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results for genetic risk, a critical factor affecting patient outcomes, were closely in line with the consensus, which was verified in univariate and multivariate analyses. Bone marrow transplantation is known as an effective treatment for AML, yielding a high rate of curability [28,29]. In the present study, no differences were observed in terms of genetic risk and bone marrow transplantation rate between the different groups.…”

Section: Discussioncontrasting

confidence: 43%

Prognostic Significance of CD56 Antigen Expression in Patients with De Novo Non-M3 Acute Myeloid Leukemia

Sun

Wan

Song

et al. 2021

BioMed Research International

View full text Add to dashboard Cite

Acute myeloid leukemia (AML) is a heterogeneous group of disorders with distinct characteristics and prognoses. Although cytogenetic changes and gene mutations are associated with AML prognosis, there is a need to identify further factors. CD56 is considered a prognostic factor for AML, which is abnormally expressed in leukemia cells. However, a clear consensus for this surface molecule is lacking, which has prompted us to investigate its prognostic significance. Bone marrow samples of de novo non-M3 AML were collected to detect CD56 expression using multiparameter flow cytometry (FCM). As a result, the CD56 expression in de novo non-M3 AML was found to be significantly higher than that in acute lymphoma leukemia (ALL, P = 0.017 ) and healthy controls ( P = 0.02 ). The X-Tile program produced a CD56 cutoff point at a relative expression level of 24.62%. Based on this cutoff point, high CD56 expression was observed in 29.21% of de novo non-M3 AML patients. CD56-high patients had a poor overall survival (OS, P = 0.015 ) compared to CD56-low patients. Bone marrow transplantation (BMT) improved OS ( P = 0.004 ), but a poor genetic risk was associated with an inferior OS ( P = 0.002 ). Compared with CD56-low patients, CD56-high patients had lower peripheral blood platelet (PLT) counts ( P = 0.010 ). Our research confirmed that high CD56 expression is associated with adverse clinical outcomes in de novo non-M3 AML patients, indicating that CD56 could be used as a prognostic marker for a more precise stratification of de novo non-M3 AML patients.

show abstract

Section: Discussioncontrasting

confidence: 43%

Prognostic Significance of CD56 Antigen Expression in Patients with De Novo Non-M3 Acute Myeloid Leukemia

Sun

Wan

Song

et al. 2021

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…Although the number of BM and umbilical cord blood HSC donations is adequate [14], Human Leukocyte Antigen (HLA) compatibility is still one of the most hindering obstacles [15]. Autologous transplantation of ex vivo expanded of HSCs is an option to circumvent the need for matched donors and avoid immune rejection and graft versus host disease [16][17][18][19][20]. Nevertheless, ex vivo expansion of HSCs remains challenging due to spontaneous differentiation and loss of self-renewal [8].…”

Section: Clinical Interest In Pluripotent Stem Cells In Hematopoiesismentioning

confidence: 99%

Hematopoietic Differentiation of Human Pluripotent Stem Cells: HOX and GATA Transcription Factors as Master Regulators

Alsayegh

Cortés-Medina

Ramos‐Mandujano

et al. 2019

View full text Add to dashboard Cite

Numerous human disorders of the blood system would directly or indirectly benefit from therapeutic approaches that reconstitute the hematopoietic system. Hematopoietic stem cells (HSCs), either from matched donors or ex vivo manipulated autologous tissues, are the most used cellular source of cell therapy for a wide range of disorders. Due to the scarcity of matched donors and the difficulty of ex vivo expansion of HSCs, there is a growing interest in harnessing the potential of pluripotent stem cells (PSCs) as a de novo source of HSCs. PSCs make an ideal source of cells for regenerative medicine in general and for treating blood disorders in particular because they could expand indefinitely in culture and differentiate to any cell type in the body. However, advancement in deriving functional HSCs from PSCs has been slow. This is partly due to an incomplete understanding of the molecular mechanisms underlying normal hematopoiesis. In this review, we discuss the latest efforts to generate human PSC (hPSC)-derived HSCs capable of long-term engraftment. We review the regulation of the key transcription factors (TFs) in hematopoiesis and hematopoietic differentiation, the Homeobox (HOX) and GATA genes, and the interplay between them and microRNAs. We also propose that precise control of these master regulators during the course of hematopoietic differentiation is key to achieving functional hPSC-derived HSCs.

show abstract

“…Our results are compatible with the previous studies which demonstrated an advantage for auto-HSCT compared to conventional chemotherapy in terms of improved LFS with no significant impact on OS. 2 , 3 , 5 , 7 , 11 , 12 In our study, the follow-up period of auto-HSCT recipients was relatively shorter than chemotherapy arm, which may be an explanation for the higher early relapse rates. We did not perform MRD analysis at the time of transplant, therefore the potential impact of MRD status on relapse incidence should also be taken into account.…”

Section: Resultsmentioning

confidence: 62%

Comparison of Post-Remission Strategies in Acute Myeloid Leukemia: Autologous Hematopoietic Stem Cell Transplantation versus Consolidation Chemotherapy

et al. 2020

View full text Add to dashboard Cite

Autologous Hematopoietic Stem Cell Transplantation (auto-HSCT) has become a therapeutic option for first-line consolidation in Acute Myeloid Leukemia (AML) patients with favorable and intermediate risk features. A total of 101 AML patients in first complete remission, who were not eligible for allogeneic HSCT, were randomized to receive intensive cytarabine-based chemotherapy or to undergo auto-HSCT. The probability of LFS was significantly better in auto-HSCT recipients compared to chemotherapy arm (43% vs 4.8%, p=0.008). At the end of 915 (30-4470) days of followup, the probability of overall survival was better in auto-HSCT group compared to chemotherapy, without statistical significance (79.2% vs 38.8%, p=0.054). Multivariate analysis revealed a significant predictive impact of cytogenetic risk status on OS (p=0.002, HR: 2.824, 95% CI: 1.445- 5.521). Auto-HSCT is considered as an effective consolidation approach in favorable and intermadiate risk AML patients.

show abstract

Autologous Hematopoietic Stem Cell Transplantation for Adults With Acute Myeloid Leukemia

Cited by 8 publications

References 11 publications

Prognostic Significance of CD56 Antigen Expression in Patients with De Novo Non-M3 Acute Myeloid Leukemia

Prognostic Significance of CD56 Antigen Expression in Patients with De Novo Non-M3 Acute Myeloid Leukemia

Hematopoietic Differentiation of Human Pluripotent Stem Cells: HOX and GATA Transcription Factors as Master Regulators

Comparison of Post-Remission Strategies in Acute Myeloid Leukemia: Autologous Hematopoietic Stem Cell Transplantation versus Consolidation Chemotherapy

Contact Info

Product

Resources

About